Shareholders approved the acquisition of Teli Pharmaceuticals, Inc., which involves issuing shares representing over 20% of Telomir's outstanding common stock. The 2023 Omnibus Incentive Plan was amended to increase the number of shares reserved for issuance from 6,500,000 to 11,500,000. The amended incentive plan also allows for the repricing of options or stock appreciation rights (SARs), including reducing their exercise or grant price. Bylaws were amended to reduce the quorum requirement for shareholder meetings to one-third of the votes entitled to be cast. Four directors, Erez Aminov, Matthew Whalen, Edward MacPherson, and Matthew Del Giudice, M.D., were elected to the Board. Salberg & Company, P.A. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Shareholders approved proposals to issue certain grants of options to non-executive Board members. The 2025 Annual Meeting of Stockholders, held on March 23, 2026, had 34,380,971 shares outstanding as of the January 23, 2026 record date, with 17,589,062 shares (approximately 51.16%) represented and voted.